Hospitals building clinical sample archives, pharmaceutical and biotechnology companies sourcing specimens for drug discovery and biomarker research, and academic and public health institutions running long-term population or disease cohort studies make up the buyer base for bio banking. What they buy is rarely one product: ultra-low-temperature freezers and liquid nitrogen storage sit alongside sample tracking systems, shipping logistics and processing consumables, all needed to keep blood, tissue, cell and nucleic acid specimens viable for years or decades, together with the clinical and demographic records tied to each sample.
Contrive Datum Insights sizes the global bio banking market at USD 83.3 billion in 2025, rising to USD 91.38 billion in 2026 and reaching USD 191.64 billion by 2034, a compound annual growth rate of 9.7%. The findings appear in the firm's report, "Bio Banking Market Size, Share & Industry Analysis, By Type (Population-Based Biobank, Disease-Oriented Biobank, Other), Application (Research, Therapeutic, Other), Product & service (Equipment & Storage Systems, Consumables & Reagents, Services), Sample type (Blood Products, Human Tissues, Cell Lines, Others), End user (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Others), and Regional Forecast, 2026-2034."
Spending Shifts From Population Archives Toward Disease-Specific Panels
Population-Based Biobank accounts for 52% of 2025 revenue, worth USD 43.32 billion, and stays the largest type line through 2034 even as its share eases to 47%; its own growth rate of 8.47% trails the market average. Disease-Oriented Biobank moves the other way, compounding at 11.4% and lifting its share of revenue from 40% to 46% as its value climbs from USD 33.32 billion to USD 88.15 billion. The same pattern shows up on every other axis: Research holds 58% of 2025 application revenue (USD 48.31 billion) while Therapeutic grows faster, at 12.38%; Equipment & Storage Systems leads product and service spending at 42% (USD 34.99 billion) while Services expands quickest at 11.87%; Blood Products leads sample type at 45% (USD 37.49 billion) while Cell Lines grows fastest at 13.26%; and Academic & Research Institutes lead end-user spending at 40% (USD 33.32 billion) while Pharmaceutical & Biotechnology Companies gain ground fastest, at 12.14%. Expansion of precision medicine and biomarker-driven drug development is the single largest contributor to this growth, and the report rates its impact high.
North America generates 38% of 2025 revenue, USD 31.65 billion, and grows to USD 67.07 billion by 2034; the United States alone accounts for USD 26.9 billion of 2025 revenue, 32.29% of the global total. Asia Pacific's share climbs from 24% to 29% over the same period as its revenue expands from USD 19.99 billion to USD 55.58 billion. Middle East and Africa sits at the bottom of the regional table throughout, holding 5% of revenue in both 2025 and 2034.
The report's scenarios sit on either side of the USD 191.64 billion base case, not in place of it. A bull case built on faster adoption of outsourced biobanking services and stronger public funding for population cohort programs would push 2034 revenue to USD 214.64 billion; a bear case in which tighter research and biopharma R&D budgets delay new cohort launches and slow the move to outsourced biobanking would hold the market to USD 172.48 billion. The report covers all five regions with country-level detail, the competitive landscape and revenue by type, application, product and service, sample type and end user from 2020 through 2034. It is delivered as a PDF, and a free sample is available on request.